AllianceBernstein’s Aegerion Pharmaceuticals AEGR Stock Holding History

AllianceBernstein’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-49,050	Closed	-$181K	–	3029
2016 Q1	$181K	Sell	49,050 -4,400	-8%	-$27.3K	﹤0.01%	2738
2015 Q4	$540K	Sell	53,450 -5,800	-10%	-$69.8K	﹤0.01%	2424
2015 Q3	$806K	Sell	59,250 -50	-0.1%	-$890	﹤0.01%	2274
2015 Q2	$1.13M	Hold	59,300	–	–	﹤0.01%	2208
2015 Q1	$1.55M	Hold	59,300	–	–	﹤0.01%	1917
2014 Q4	$1.24M	Hold	59,300	–	–	﹤0.01%	2073
2014 Q3	$1.98M	Hold	59,300	–	–	﹤0.01%	1721
2014 Q2	$1.9M	Hold	59,300	–	–	﹤0.01%	1813
2014 Q1	$2.73M	Sell	59,300 -472,879	-89%	-$27.7M	﹤0.01%	1474
2013 Q4	$37.8M	Buy	532,179 +471,179	+772%	+$36M	0.03%	511
2013 Q3	$5.23M	Buy	61,000 +265	+0.4%	+$22.5K	0.01%	1043
2013 Q2	$3.85M	Buy	+60,735	New	+$3.22M	﹤0.01%	1148

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AllianceBernstein's AEGR Position: Q2 2016 in Review

AllianceBernstein sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 49,050 shares — an estimated $181K sold.

AllianceBernstein first reported a position in AEGR in Q2 2013 and held it in 12 quarters. The position peaked at $37.8M in Q4 2013. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

AllianceBernstein reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
AllianceBernstein sold 49,050 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $181K.
AllianceBernstein first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
AllianceBernstein's Aegerion Pharmaceuticals position peaked at $37.8M in Q4 2013.
71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on AllianceBernstein's 13F filing for Q2 2016, filed 11 Aug 2016.